Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:プロスタグランジン(PG)関連薬単剤で治療中の正常眼圧緑内障(NTG)患者にブリモニジンを追加し,有効性と安全性について報告した。対象および方法:3か月以上PG関連薬で治療中のNTG患者17例17眼を対象とした。ブリモニジンを追加し,1か月後,3か月後,6か月後,12か月後に眼圧を測定した。局所の安全性は充血,掻痒感,角膜障害について評価した。結果:ブリモニジン追加により,眼圧は,追加前11.5±1.5mmHg,1か月後9.7±1.6mmHg(p<0.001),3か月後9.4±1.4mmHg(p<0.0001),6か月後9.9±1.9mmHg(p<0.0005),12か月後9.9±1.8mmHg(p<0.0005)と,各時点で有意に下降した。局所の副作用について有意な変化はなかった。結論:PG関連薬で治療中のNTG患者へのブリモニジンの追加により,さらなる眼圧下降効果が得られ,その効果が12か月間持続した。
Abstract. Purpose:To report the effect of adding brimonidine ophthalmic solution to topical treatment with prostaglandin analogue. Subjects and Method:This study involved 17 eyes of 17 patients(4 males, 13 females;age range:38 to 86 years, average 72 years)who were being treated by topical prostaglandin analogue for 3 months or longer. They started receiving 0.1% brimonidine additionally. Intraocular pressure(IOP), ocular surface damage, conjunctival injection and itching were checked after 1, 3, 6 and 12 months of treatment. Result:IOP averaged 11.5±1.5 mmHg before additional treatment, 9.7±1.6 mmHg(p<0.001)after 1 month, 9.4±1.4 mmHg(p<0.0001)after 3 months, 9.9±1.9 mmHg(p<0.0005)after 6 months, and 9.9±1.8 mmHg(p<0.0005)after 12 months. IOP thus decreased significantly after additional treatment. No statistical difference in ocular symptoms was observed during the course of observation. Conclusion:Brimonidine ophthalmic solution added to topical treatment with prostaglandin analogue induced further decrease in IOP for 12 months.
Copyright © 2015, Igaku-Shoin Ltd. All rights reserved.